FINANCIAL INSTRUMENTS (Tables)

6 Months Ended

Jun. 30, 2026

Financial Instruments

Schedule of Financial instruments measured at fair value


										Fair value hierarchy
		June 30, 2026								December 31, 2025
		Level 2				Level 3				Level 2				Level 3
Assets measured at fair value:
Derivative financial instruments (a)			1,060								1,432
Investments in financial assets measured at fair value through profit and loss (b)		$					25,000			$					14,656

Financial liability measured at fair value through profit and loss		$					240			$					319

Schedule of  financial instruments are measured at fair value through profit or loss


		June 30,				December 31,
		2026				2025
Financial assets at fair value through profit or loss:

Neurolief (1)		$	11,452			$	5,366
Stella			5,631				5,000
Axis (2)			2,608				2,377
Tangient (3)			1,713				1,538
Hopemark (4)			1,515				—
BrainStim (5)			1,063				—
Active Recovery (6)			500				—
DGR			268				250
Radial (7)			250				125

Total financial assets at fair value through profit or loss			25,000				14,656

Financial liabilities at fair value through profit or loss:

Neurolief (1)			(240	)			(319	)

Total financial liabilities at fair value through profit or loss			(240	)			(319	)

[custom:DisclosureOfWarrantsLiabilityExplanatory]


		For the six months ended June 30, 2026				For the year ended December 31, 2025

Balance as of January 1,			14,656				—
Investment in financial instruments			10,125				14,494
Gain from remeasurement to fair value through profit or loss			219				162

Balance as of the end of the period			25,000				14,656